Sanifit is a clinical-stage biopharmaceutical company focused on treatments for progressive vascular calcification disorders. The company started activities in 2007 as a spin-off from the University of the Balearic Islands, and has offices in Spain and the USA. Sanifit’s lead compound is SNF472, a novel small molecule that is a selective and potent inhibitor of hydroxyapatite (HAP) crystallisation, the final common pathway t...
Sanifit is a clinical-stage biopharmaceutical company focused on treatments for progressive vascular calcification disorders. The company started activities in 2007 as a spin-off from the University of the Balearic Islands, and has offices in Spain and the USA. Sanifit’s lead compound is SNF472, a novel small molecule that is a selective and potent inhibitor of hydroxyapatite (HAP) crystallisation, the final common pathway that leads to vascular calcification. SNF472 is in clinical development for the treatment of calciphylaxis or CUA (calcific uremic arteriolopathy) in patients undergoing dialysis.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.